Johnson & Johnson (New York Stock Exchange:JNJ)
| Market Cap | 643.64B+50.9% |
| Revenue (ttm) | 97.93B+8.1% |
| Net Income | 21.04B-7.2% |
| EPS | 8.63-7.7% |
| Shares Out | 2.41B |
| PE Ratio | 30.88 |
| Forward PE | 20.91 |
| Dividend | $5.28(1.98%) |
| Ex-Dividend Date | Aug 25, 2026 |
| Volume | 5,967,693 |
| Open | 268.51 |
| Previous Close | 269.12 |
| Day's Range | 266.73 - 270.10 |
| 52-Week Range | 173.33 - 281.07 |
| Beta | 0.23 |
| Analysts | Buy |
| Price Target | 284.79(+6.63%) |
| Earnings Date | Oct 13, 2026 |
About JNJ
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$JNJ stock is featured in our Insider Score Rankings, Congress Trading, and Insider Trades datasets.
→ All Stock ListsCongress Trading
Recent trades of JNJ by members of U.S. Congress
| Politician | Type | Traded |
|---|---|---|
| Rich McCormickHouse / R | Sale$1.00K – $15.00K | Jul 30, 2026 |
| Thomas H. KeanHouse / R | Sale$1.00K – $15.00K | Jun 29, 2026 |
| Thomas KeanHouse / R | Sale$1.00K – $15.00K | Jun 28, 2026 |
| Thomas H. KeanHouse / R | Sale$1.00K – $15.00K | Jun 2, 2026 |
| Thomas KeanHouse / R | Sale$1.00K – $15.00K | Jun 1, 2026 |
| Thomas H. KeanHouse / R | Sale$1.00K – $15.00K | Mar 26, 2026 |
| Thomas KeanHouse / R | Sale$1.00K – $15.00K | Mar 25, 2026 |
| John BoozmanSenate / R | Sale$1.00K – $15.00K | Mar 19, 2026 |
Recently reported changes in JNJ holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by JNJ's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
JNJ Estimated quarterly lobbying spending
Source: U.S. Senate LDA
JNJ Revenue by Segment or Geography
Source: SEC EDGAR (10-Q/10-K)
U.S. Patents
New JNJ patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to JNJ from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in JNJ
| ETF | Est. Holding Size |
|---|---|
| VTIVanguard Morningstar Total Stock Market ETF | $19.65B |
| VOOVanguard S&P 500 ETF | $16.20B |
| IVViShares Core S&P 500 ETF | $8.76B |
| SPYState Street SPDR S&P 500 ETF | $7.95B |
| VTVVanguard Morningstar Value ETF | $5.88B |
| XLVState Street Health Care Select Sector SPDR ETF | $4.78B |
Estimated from each fund’s disclosed top holdings × AUM
JNJ Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from JNJ’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score